All In Biotech

Drug Trial Radar · NCT00829582

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (AnthimTM) [Elusys Protocol Number AH-102]

Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Planned (sponsor's estimate)

Start

Feb 2009

Primary completion

Jul 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Title: Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (AnthimTM) Population: This study will determine the safety, tolerability and pharmacokinetics of a single iv dose of ETI-204 in subjects 18 to 50 years of age. Three cohorts will be studied sequentially: subjects receiving 120 mg, 240 mg and 360 mg of ETI-204. The study will be randomized, double-blind, and stratified by gender. Each cohort will contain 15 subjects (including at least four females), twelve who will receive ETI-204 and three who will receive placebo. Study Objectives: To determine the safety, tolerability and pharmacokinetics of ETI-204 following a single intravenous administration.

Conditions

  • Healthy Volunteers

Interventions

  • ETI-204, "Anthim"Drug

    single intravenous infusion of 120, 240 or 360 mg of ETI-204

  • placeboOther

    single intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evidence of clinical safety following the infusionTime frame: 42 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Osu, 5084 Graves 333 W Tenth Ave

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.